Senate committee panel puts drug industry CEOs on defensive over pricing
The Senate Finance Committee grilled executives from seven of the biggest drugmakers about the dramatic rise in drug costs.
AbbVie wades into crowded multiple myeloma market
The drugmaker said Monday that it had signed a deal with Teneobio to develop a BCMA-targeting bispecific antibody.
The Human Algorithm: What AI Can’t Replace in Pharma Engagement
At a time when AI is reshaping pharma, Reverba Global CEO Cheryl Lubbert explained in an interview why empathy, context, and ethics still require a human touch.
China’s BeiGene gets FDA breakthrough therapy designation for BTK inhibitor
While zanubrutinib showed a higher response rate in the same mantle cell lymphoma setting for which Imbruvica is approved, the Phase II study enrolled younger, less heavily pretreated patients than those in Imbruvica's pivotal trial.
Roche’s Venclexta data from ASH position drug as new AML standard of care, doctor says
The drug, combined with Celgene's Vidaza, Otsuka's Dacogen or low-dose cytarabine, showed strong response rates in elderly and unfit AML patients, historically a hard-to-treat population.
Morphic partners with investor AbbVie on integrin inhibitor development
The Waltham, Massachusetts-based company will receive $100 million, in addition to potential undisclosed milestones and royalties.
Momenta’s biosimilars pullback could portend further industry exits
Expert says that biosimilars' pricing discounts and lower-than-expected patient populations could make the market less attractive for smaller players.
presented by
The Top 5 Home Care Franchise Opportunities in the U.S.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
Apple Watch’s role in clinical trials unclear, but wearables have a big role to play
Wearable devices are growing in importance for collecting data in trials, but their utility may vary based on patient demographics and disease state.
Report blames gaming of patent system for high drug prices
Most drugs named are biologics, and manufacturing trade secrets make competition especially tricky, legal expert says.
Biosimilars market set to nearly quadruple in next five years, report finds
Market forecast rosy, though market in United States remains young.
Chicago’s $69.7 billion healthcare industry makes it a hub for innovation
In a new report, the Health Care Council of Chicago, an initiative of Matter and Leavitt Partners, outlined the current status of Chicago's healthcare ecosystem.
What Are Healthcare Organizations Getting Wrong about Email Security?
A new report by Paubox calls for healthcare IT leaders to dispose of outdated assumptions about email security and address the challenges of evolving cybersecurity threats.
AbbVie to buy oncology drug-maker Stemcentrx for at least $5.8B
The centerpiece of Stemcentrx's work is rovalpituzumab tesirine (Rova-T), a biomarker-specific therapy derived from cancer stem cells that is in registrational trials to treat small-cell lung cancer.
Looks like venture investors aren’t too bothered by the gyrating life sciences markets
"I'm a skeptic of public market valuations, but a true believer in biotechnology," said Hans Hinrichs, managing director of Silicon Valley Bank's Life Sciences and Healthcare Group. "We're probably sitting on the biggest opportunity in the history of investment."
Morning Read: Report tracks steep drug price increases by pharma companies
Also, an outbreak of VIP syndrome at hospitals, fashionable prosthetics and Samsung's advancement of biosimilar drug for rheumatoid arthritis.
Where Hillary & Co. have it wrong. Three reasons biopharmaceutical manufacturers are not the bogeymen many believe them to be.
The manufacturers seldom get credit for things they are doing right to the benefit to all concerned.
5 must-read stories for the holiday weekend, from medical devices exempted by the FDA to Google’s competition in crowdsourcing public health
MedHeads won't be airing today and content is light due to the holiday weekend, but you can check out the top five stories from the week wherever you choose to relax. Happy Independence Day!